Loading..

Vertex Pharmaceuticals Incorporated (VRTX) Report Analysis

Corporate Events

Neutral

Vertex Pharmaceuticals Incorporated Presents at...

2022-06-16 19:39:00

Vertex Pharmaceuticals Incorporated Presents at 5th LSX USA Congress & CEO Forums, Jun-21-2022 . Venue: Boston, United States.

Positive

Vertex to Present Data Demonstrating Significan...

2022-06-10 15:00:00

Vertex Pharmaceuticals Incorporated announced that five scientific abstracts on the company’s portfolio of cystic fibrosis (CF) medicines will...

Neutral

Vertex Pharmaceuticals Incorporated Presents at...

2022-06-09 03:22:00

Vertex Pharmaceuticals Incorporated Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-15-2022 01:20 PM. Venue: Terranea ...

Positive

Vertex Pharmaceuticals Incorporated Announces I...

2022-06-08 12:00:00

Vertex Pharmaceuticals Incorporated announced the U.S. Food and Drug Administration (FDA) has granted inaxaplin (VX-147) Breakthrough Therapy ...

Positive

Vertex Pharmaceuticals Incorporated to Present ...

2022-05-31 12:00:00

Vertex Pharmaceuticals Incorporated announced three abstracts, including two oral presentations and one poster, detailing data on type 1 diabe...

Neutral

Vertex Pharmaceuticals Incorporated Presents at...

2022-05-31 12:00:00

Vertex Pharmaceuticals Incorporated Presents at 82nd Scientific Sessions of the American Diabetes Association conference, Jun-03-2022 through ...

Neutral

Vertex Pharmaceuticals Incorporated Presents at...

2022-05-29 16:32:00

Vertex Pharmaceuticals Incorporated Presents at Advanced Manufacturing and Processing Conference, Jun-01-2022 through Jun-03-2022. Venue: Hyat...

Positive

Vertex Pharmaceuticals Incorporated (NasdaqGS :...

2022-05-23 00:00:00

Vertex Pharmaceuticals Incorporated (NasdaqGS : VRTX) acquired Complement Portfolio of Catalyst Biosciences, Inc. for $60 million on May 19, 2...

Negative

Vertex Pharmaceuticals Incorporated Elects Suke...

2022-05-18 14:30:00

Vertex Pharmaceuticals Incorporated announced that Suketu Upadhyay elected to its board of directors as an independent director. Upadhyay is a...

Positive

Vertex Pharmaceuticals Incorporated Announces F...

2022-05-17 10:45:00

Vertex Pharmaceuticals Incorporated announced plans to build another 344,000 square foot facility in the Seaport to support the company’s cont...

Neutral

Vertex Pharmaceuticals Incorporated Reiterates ...

2022-05-05 20:01:00

Vertex Pharmaceuticals Incorporated reiterated earning guidance for 2022. The Company expects product revenue guidance of $8.4 to $8.6 billion.

Positive

Vertex Pharmaceuticals Incorporated Provides Up...

2022-05-02 12:30:00

--Vertex Pharmaceuticals Incorporated provided updates on its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully ...

Neutral

Vertex Pharmaceuticals Incorporated, Q1 2022 Ea...

2022-04-21 20:05:00

Vertex Pharmaceuticals Incorporated, Q1 2022 Earnings Call, May 05, 2022

Neutral

Vertex Pharmaceuticals Incorporated to Report Q...

2022-04-21 20:05:00

Vertex Pharmaceuticals Incorporated announced that they will report Q1, 2022 results After-Market on May 05, 2022

Positive

Vertex Pharmaceuticals Incorporated Announces H...

2022-04-20 21:45:00

Vertex Pharmaceuticals Incorporated announced that Health Canada has granted Marketing Authorization for the expanded use of TRIKAFTA® (elexac...

Neutral

Vertex Pharmaceuticals Incorporated - Sharehold...

2022-04-07 20:06:00

AGM

Neutral

Vertex Pharmaceuticals Incorporated, Annual Gen...

2022-04-07 20:06:00

Vertex Pharmaceuticals Incorporated, Annual General Meeting, May 18, 2022, at 09:30 US Eastern Standard Time. Agenda: To elect the 11 director...

Positive

Vertex Pharmaceuticals Incorporated Announces S...

2022-03-31 12:00:00

Vertex Pharmaceuticals Incorporated announced positive results from two Phase 2 proof-of-concept (POC) studies that investigated treatment wit...

Neutral

American Kidney Fund Announces Support from Ver...

2022-03-29 13:00:00

The American Kidney Fund (AKF) announced that Vertex Pharmaceuticals Inc. is providing support for AKF’s education and awareness campaign abou...

Neutral

Vertex Pharmaceuticals Incorporated Presents at...

2022-03-29 08:36:00

Vertex Pharmaceuticals Incorporated Presents at Pharma Manufacturing World Summit, Mar-29-2022 . Venue: Boston Marriott Copley Place, Boston, ...

Neutral

Executive Platforms Inc., Pharma Manufacturing ...

2022-03-21 14:57:00

Executive Platforms Inc., Pharma Manufacturing World Summit, Mar 29, 2022 through Mar 30, 2022. Venue: Boston Marriott Copley Place, Boston, M...

Neutral

American Diabetes Association, Inc., 82nd Scien...

2022-03-16 13:54:00

American Diabetes Association, Inc., 82nd Scientific Sessions of the American Diabetes Association conference, Jun 03, 2022 through Jun 07, 20...

Positive

Vertex Pharmaceuticals Seeks Acquisitions

2022-02-09 21:46:00

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) is looking for acquisitions. The company said "We expect to continue to identify and evalu...

Neutral

Tranche Update on Vertex Pharmaceuticals Incorp...

2022-02-09 16:38:00

From October 1, 2021 to December 31, 2021, the company has repurchased 1,986,042 shares, representing 0.78% for $358.14 million. With this, th...

Neutral

Vertex Pharmaceuticals Incorporated has filed a...

2022-02-09 00:00:00

Vertex Pharmaceuticals Incorporated has filed a Shelf Registration. Security Name: Common Stock Security Name: Debt Securities Securi...

Neutral

The Goldman Sachs Group, Inc., Goldman Sachs 43...

2022-02-08 07:31:00

The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022. Venue: Terranea Reso...

Neutral

Vertex Pharmaceuticals Incorporated - Special Call

2021-12-01 12:37:00

To discuss the positive results from Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis

Positive

Vertex Pharmaceuticals Incorporated Announces P...

2021-12-01 12:30:00

Vertex Pharmaceuticals Incorporated announced that, in a Phase 2 proof-of-concept (POC) study in patients with APOL1-mediated focal segmental ...

Positive

Vertex Pharmaceuticals Incorporated Receives CH...

2021-11-12 12:27:00

Vertex Pharmaceuticals Incorporated announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP)...

Positive

Arbor Biotechnologies, Inc. announced that it h...

2021-11-09 00:00:00

On November 9, 2021, Arbor Biotechnologies, Inc. closed the transaction. The transaction was led by new investors Temasek Holdings (Private) L...

Neutral

Tranche Update on Vertex Pharmaceuticals Incorp...

2021-11-03 16:18:00

From July 1, 2021 to September 30, 2021, the company has repurchased 3,293,161 shares, representing 1.27% for $642.2 million. With this, the c...

Positive

Vertex Pharmaceuticals Incorporated Revises Rev...

2021-11-02 20:01:00

Vertex Pharmaceuticals Incorporated raised full-year 2021 product revenue guidance to $7.4 to $7.5 billion compared to previous guidance of $7...

Positive

Arbor Biotechnologies, Inc. announced that it e...

2021-10-29 00:00:00

Arbor Biotechnologies, Inc. announced that it will issue 12,975,254 series B preferred shares at a price of $16.57 per share for gross proceed...

Neutral

Ginkgo Bioworks Holdings, Inc., Annual Ferment ...

2021-10-28 12:00:00

Ginkgo Bioworks Holdings, Inc., Annual Ferment Conference, Oct 28, 2021.

Neutral

Vertex Pharmaceuticals Incorporated Presents at...

2021-10-28 12:00:00

Vertex Pharmaceuticals Incorporated Presents at Annual Ferment Conference, Oct-28-2021 . Speakers: Reshma Kewalramani, CEO, President & Director.

Positive

Vertex Pharmaceuticals Incorporated's Supplemen...

2021-10-27 16:07:00

Vertex Pharmaceuticals Incorporated announced that its Supplement to a New Drug Submission for PrTRIKAFTA® (elexacaftor/tezacaftor/ivacaftor a...

Positive

Vertex and Mammoth Biosciences Announce Collabo...

2021-10-26 13:00:00

Vertex Pharmaceuticals Incorporated and Mammoth Biosciences, Inc. announced a new partnership to develop in vivo gene-editing therapies for tw...

Neutral

Vertex Pharmaceuticals Incorporated, Q3 2021 Ea...

2021-10-22 12:00:00

Vertex Pharmaceuticals Incorporated, Q3 2021 Earnings Call, Nov 02, 2021

Neutral

Vertex Pharmaceuticals Incorporated to Report Q...

2021-10-22 12:00:00

Vertex Pharmaceuticals Incorporated announced that they will report Q3, 2021 results After-Market on Nov 02, 2021

Positive

Vertex to Present Long-Term Data Demonstrating ...

2021-10-19 12:00:00

Vertex Pharmaceuticals Incorporated announced that five scientific abstracts about the company’s portfolio of cystic fibrosis (CF) medicines w...

Neutral

Molecular Templates, Inc. Receives Notice from ...

2021-10-18 11:31:00

On October 15, 2021, Molecular Templates Inc. received notice from Vertex Pharmaceuticals Incorporated (Vertex") that Vertex has decided to te...

Positive

Vertex Pharmaceuticals Incorporated Announces P...

2021-10-18 11:30:00

Vertex Pharmaceuticals Incorporated announced positive Day 90 data for the first patient from the Phase 1/2 clinical trial of VX-880, an inves...

Neutral

Vertex Pharmaceuticals Incorporated Presents at...

2021-09-30 22:23:00

Vertex Pharmaceuticals Incorporated Presents at Cell & Gene Meeting on the Mesa, Oct-12-2021 . Venue: Carlsbad, California, United States.

Neutral

Vertex Pharmaceuticals Incorporated Presents at...

2021-09-28 14:33:00

Vertex Pharmaceuticals Incorporated Presents at Transparency & Aggregate Spend, Dec-06-2021 through Dec-10-2021. Venue: Hilton Philadelphia at...

Neutral

Informa plc, Transparency & Aggregate Spend, De...

2021-09-27 17:31:00

Informa plc, Transparency & Aggregate Spend, Dec 06, 2021 through Dec 10, 2021. Venue: Hilton Philadelphia at Penn's Landing, Philadelphia, Pe...

Positive

Vertex Pharmaceuticals Incorporated Announces I...

2021-09-22 15:16:00

Vertex Pharmaceuticals Incorporated announced its Supplement to a New Drug Submission for PrKALYDECO® (ivacaftor) has been accepted for priori...

Positive

Vertex Pharmaceuticals Incorporated Letter of I...

2021-09-17 20:19:00

Vertex Pharmaceuticals Incorporated (Canada) announced that it has signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Allian...

Neutral

Vertex Pharmaceuticals Incorporated Presents at...

2021-09-16 14:42:00

Vertex Pharmaceuticals Incorporated Presents at Cell & Gene Therapy Bioprocessing & Commercialization, Sep-20-2021 . Speakers: Stacey Veysey, ...

Neutral

Vertex Pharmaceuticals Incorporated Provides Ea...

2021-09-15 15:00:00

Vertex Pharmaceuticals Incorporated provided earnings guidance for the year 2021. For the period, the company raised revenue guidance by $500 ...

Neutral

Vertex Pharmaceuticals Incorporated Presents at...

2021-09-15 13:42:00

Vertex Pharmaceuticals Incorporated Presents at 10th Annual Sickle Cell Disease Therapeutics Conference, Sep-15-2021 03:25 PM. Speakers: Willi...

Neutral

Vertex Pharmaceuticals Incorporated Presents at...

2021-09-13 12:00:00

Vertex Pharmaceuticals Incorporated Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-15-2021 11:00 AM. Venue: New Wind...

Positive

Obsidian Therapeutics, Inc. announced that it h...

2021-09-09 00:00:00

On September 9, 2021, Obsidian Therapeutics, Inc. closed the transaction. The company issued 76,158,940 shares and received $114,999,999.4 in...

Neutral

Informa plc, Cell & Gene Therapy Bioprocessing ...

2021-09-08 23:01:00

Informa plc, Cell & Gene Therapy Bioprocessing & Commercialization, Sep 20, 2021 through Sep 30, 2021.

Neutral

Global Blood Therapeutics, Inc., Sickle Cell Di...

2021-09-08 21:05:00

Global Blood Therapeutics, Inc., Sickle Cell Disease Association of America, Inc., 10th Annual Sickle Cell Disease Therapeutics Conference, S...

Neutral

LSX Ltd, 5th LSX USA Congress & CEO Forums, Jun...

2021-09-04 07:34:00

LSX Ltd, 5th LSX USA Congress & CEO Forums, Jun 21, 2022 through Jun 22, 2022. Venue: Boston, United States.

Positive

Vertex Pharmaceuticals Incorporated Announces P...

2021-08-26 11:00:00

Vertex Pharmaceuticals Incorporated announced publication in The new England Journal of Medicine(NEJM) of results from a Phase 3 study of TRIK...

Positive

Vertex Pharmaceuticals Incorporated and Arbor B...

2021-08-24 11:00:00

Vertex Pharmaceuticals Incorporated and Arbor Biotechnologies (Arbor) announced a new collaboration to enhance efforts in developing ex vivo e...

Neutral

Vertex Pharmaceuticals Incorporated Presents at...

2021-08-20 20:21:00

Vertex Pharmaceuticals Incorporated Presents at World Orphan Drug Congress USA 2021, Aug-26-2021 01:00 PM. Venue: Gaylord National Resort & Co...

Neutral

Terrapinn Holdings Ltd, World Orphan Drug Congr...

2021-08-20 17:31:00

Terrapinn Holdings Ltd, World Orphan Drug Congress USA 2021, Aug 25, 2021 through Aug 27, 2021. Venue: Gaylord National Resort & Convention C...

Positive

Obsidian Therapeutics, Inc. announced that it e...

2021-08-19 00:00:00

Obsidian Therapeutics, Inc. announced that it will issue 7,6187,917 series B Preferred shares at an issue price of $1.51 per share for gross p...

Neutral

Vertex Pharmaceuticals Incorporated Presents at...

2021-08-14 17:42:00

Vertex Pharmaceuticals Incorporated Presents at Supply Chain & Logistics for Cell Therapies Summit, Oct-26-2021 through Oct-28-2021. Presentat...

Neutral

Hanson Wade Limited, Supply Chain & Logistics f...

2021-08-14 15:18:00

Hanson Wade Limited, Supply Chain & Logistics for Cell Therapies Summit, Oct 26, 2021 through Oct 28, 2021.

Neutral

Vertex Pharmaceuticals Incorporated Presents at...

2021-08-05 08:52:00

Vertex Pharmaceuticals Incorporated Presents at Pharma & Patient USA, Nov-02-2021 10:00 AM. Speakers: Gokul Gopalan, VP, Global Medical Affairs.

Neutral

Reuters Events, Pharma & Patient USA, Nov 02, 2...

2021-08-05 03:58:00

Reuters Events, Pharma & Patient USA, Nov 02, 2021 through Nov 04, 2021.

Negative

Vertex Pharmaceuticals Incorporated Appoints St...

2021-08-04 12:30:00

Vertex Pharmaceuticals Incorporated announced that Stuart A. Arbuckle has been appointed as the company’s Executive Vice President, Chief Oper...

Neutral

Tranche Update on Vertex Pharmaceuticals Incorp...

2021-07-30 16:11:00

From June 23, 2021 to June 30, 2021, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has complete...

Neutral

Vertex Pharmaceuticals Incorporated Provides Ea...

2021-07-29 20:01:00

Vertex Pharmaceuticals Incorporated increased its full-year 2021 product revenue guidance based on strong year-to-date performance and the exp...

Positive

Vertex Pharmaceuticals Incorporated Initiates P...

2021-07-19 12:00:00

Vertex Pharmaceuticals Incorporated announced that it has begun a Phase 2 proof-of-concept (POC) study in acute pain following bunionectomy su...

Neutral

Vertex Pharmaceuticals Incorporated, Q2 2021 Ea...

2021-07-16 20:01:00

Vertex Pharmaceuticals Incorporated, Q2 2021 Earnings Call, Jul 29, 2021

Neutral

Vertex Pharmaceuticals Incorporated to Report Q...

2021-07-16 20:01:00

Vertex Pharmaceuticals Incorporated announced that they will report Q2, 2021 results After-Market on Jul 29, 2021

Neutral

Vertex Pharmaceuticals Incorporated Presents at 5th LSX USA Congress & CEO Forums, Jun-21-2022

2022-06-16 19:39:00

Vertex Pharmaceuticals Incorporated Presents at 5th LSX USA Congress & CEO Forums, Jun-21-2022 . Venue: Boston, United States.

Positive

Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference

2022-06-10 15:00:00

Vertex Pharmaceuticals Incorporated announced that five scientific abstracts on the company’s portfolio of cystic fibrosis (CF) medicines will be presented at the European Cystic Fibrosis Society's (ECFS) 45th European Cystic Fibrosis Conference held June 8-11, 2022, in Rotterdam, the Netherlands. Vertex will present the first analysis of data collected in the U.S. CF Foundation Patient Registry (CFFPR) of over 16,000 people with CF treated with TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for an average of nine months. This first interim analysis of an ongoing five-year post-authorization study (abstract WS22.05) showed that real-world treatment with TRIKAFTA® was associated with improved lung function and a 77% reduced risk of pulmonary exacerbations compared to pre-TRIKAFTA® baseline, as well as an 87% lower risk of lung transplant and a 74% lower risk of death, compared to the historical 2019 U.S. CFFPR population. No new safety concerns were identified. Vertex will also present data comparing the annual rate of lung function change in people with CF ages 12 years and older with two F508del mutations (F/F) or one F508del mutation and one minimal function mutation (F/MF) treated with TRIKAFTA® in pivotal studies and an open-label extension study compared to propensity-score matched historical CFTR-modulator-untreated controls from the U.S. CFFPR (abstract WS22.04). Results show that TRIKAFTA® demonstrated on average no decrease in ppFEV1 over a two-year period in this population, in contrast to declines seen in the matched controls. The analysis indicates that treatment with TRIKAFTA® has a significant impact on the trajectory of CF lung disease. Additionally, Vertex will present data from a long-term real-world study demonstrating that initiating KALYDECO® (ivacaftor) early in life (ages 6-10 years) preserves lung function to a greater extent than if KALYDECO® is initiated at an older age (abstract WS17.03). These results show the importance of early initiation of KALYDECO® for eligible patients.

Neutral

Vertex Pharmaceuticals Incorporated Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-15-2022 01:20 PM

2022-06-09 03:22:00

Vertex Pharmaceuticals Incorporated Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-15-2022 01:20 PM. Venue: Terranea Resort, Rancho Palos Verdes, California, United States.

Positive

Vertex Pharmaceuticals Incorporated Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA

2022-06-08 12:00:00

Vertex Pharmaceuticals Incorporated announced the U.S. Food and Drug Administration (FDA) has granted inaxaplin (VX-147) Breakthrough Therapy Designation for APOL1-mediated focal segmental glomerulosclerosis (FSGS) and the European Medicines Agency (EMA) has granted inaxaplin Priority Medicines (PRIME) designation for APOL1-mediated chronic kidney disease (AMKD). Inaxaplin is the first investigational therapy aimed at treating the underlying cause of AMKD. The FDA's Breakthrough Therapy Designation is intended to expedite development and review of medicines that aim to address a serious condition with preliminary clinical evidence indicating that the drug may demonstrate substantial improvement over existing treatments on one or more clinically significant endpoints. The Breakthrough Therapy Designation was granted based on the Phase 2 clinical study of inaxaplin in patients with APOL1-mediated FSGS, a form of AMKD. The EMA’s PRIME designation is a regulatory mechanism that provides early and proactive support to developers of promising medicines, to optimize the generation of robust data and enable accelerated assessment so these medicines can potentially reach patients faster. The goal of PRIME is to help patients benefit as early as possible from innovative new therapies that have the potential to significantly address an unmet medical need. PRIME designation was granted based on clinical proof-of-concept data from Vertex’s Phase 2 study of inaxaplin in APOL1-mediated FSGS. Inaxaplin is only the second nephrology product to be granted PRIME designation. The company now holds three of the approximately 70 non-oncological PRIME designations granted to date, including its two PRIME designations for exagamglogene autotemcel (exa-cel), formerly known as CTX001, one for transfusion-dependent beta thalassemia and one for sickle cell disease. In the US, this is the ninth breakthrough therapy designation granted to Vertex across its portfolio programs.

Positive

Vertex Pharmaceuticals Incorporated to Present New Data on VX-880 Clinical Trial

2022-05-31 12:00:00

Vertex Pharmaceuticals Incorporated announced three abstracts, including two oral presentations and one poster, detailing data on type 1 diabetes (T1D) and its Phase 1/2 trial of VX-880, a stem cell-derived, fully differentiated pancreatic islet cell replacement therapy, have been accepted for presentation during the American Diabetes Association 82nd Annual Scientific Sessions Conference held June 3-7, 2022 in New Orleans, Louisiana. Abstract and publication #259-OR entitled “Stem Cell-Derived, Fully Differentiated Islet Cells for Type 1 Diabetes,” will be presented on Monday, June 6, 2022 at 9:00 a.m. CDT during the oral presentation session “Other Therapeutic Agents,” which runs from 8:00 to 10:00 a.m. CDT. The abstract posted today details results from the Phase 1/2 clinical trial, demonstrating VX-880 can restore insulin production and glucose control in T1D. Data will be updated and additional information will be presented at the conference. Abstract and publication #92-OR entitled “Persistence of Impaired Awareness of Hypoglycemia, Severe Hypoglycemic Events and Suboptimal Glycemic Control Despite Advanced Diabetes Technologies,” to be presented Saturday, June 4, 2022 at 1:45 p.m. CDT during the oral presentation session “Glucose Monitoring and Sensing,” which runs from 1:45 to 3:45 p.m. CDT. The abstract posted today, describing an online survey of 2,044 adults with T1D in the T1D Exchange registry and online communities, shows that in patients with high rates of diabetes technology adoption, such as continuous glucose monitoring, insulin pumps and hybrid closed loop systems, impaired awareness of hypoglycemia (IAH) and severe hypoglycemic events (SHEs) persist, with a substantial proportion of patients not achieving target glycemic control, indicating the need for novel T1D treatments. Abstract and poster #652-P entitled “Gaps Remain in Achieving Target T1D Glycemic Goals Despite Advanced Technologies,” will be available as part of the general poster session to be held Saturday, June 4, 2022 from 11:30 a.m. to 2:30 p.m. CDT. The abstract posted today highlights that, despite improvements in glycemic control with diabetes technologies, many patients with T1D are still unable to achieve clinical targets and experience severe hypoglycemia, emphasizing the need for novel T1D treatments.

Neutral

Vertex Pharmaceuticals Incorporated Presents at 82nd Scientific Sessions of the American Diabetes Association conference, Jun-03-2022 through Jun-07-2022

2022-05-31 12:00:00

Vertex Pharmaceuticals Incorporated Presents at 82nd Scientific Sessions of the American Diabetes Association conference, Jun-03-2022 through Jun-07-2022. Venue: New Orleans, Louisiana, United States. Presentation Date(s): Jun-04-2022. Jun-06-2022.

Neutral

Vertex Pharmaceuticals Incorporated Presents at Advanced Manufacturing and Processing Conference, Jun-01-2022 through Jun-03-2022

2022-05-29 16:32:00

Vertex Pharmaceuticals Incorporated Presents at Advanced Manufacturing and Processing Conference, Jun-01-2022 through Jun-03-2022. Venue: Hyatt Regency Bethesda, Bethesda, Maryland, United States. Presentation Date & Speakers: Jun-01-2022, Carla Luciani. Jun-02-2022, Carla Luciani.

Positive

Vertex Pharmaceuticals Incorporated (NasdaqGS : VRTX) acquired Complement Portfolio of Catalyst Biosciences, Inc. for $60 million.

2022-05-23 00:00:00

Vertex Pharmaceuticals Incorporated (NasdaqGS : VRTX) acquired Complement Portfolio of Catalyst Biosciences, Inc. for $60 million on May 19, 2022. Vertex Pharmaceuticals retained $5 million as a hold-back until one year after the closing to satisfy certain post-closing indemnification obligations. Perella Weinberg Partners acted as financial advisor to Catalyst Biosciences, Inc. Stephen Thau, David Schwartz, John Narducci, Shana Solomon, Jason D. Flaherty, Albert Vanderlaan, Beth Goldman and Thora Johnson of Orrick, Herrington & Sutcliffe LLP legal advisors to Catalyst Biosciences and Potter Anderson & Corroon LLP acted as legal advisors to Catalyst Biosciences, Inc. Vertex Pharmaceuticals Incorporated (NasdaqGS : VRTX) completed the acquisition of Complement Portfolio of Catalyst Biosciences, Inc. on May 19, 2022. As on May 12, 2022, Board of Directors of Catalyst discussed the offers received and unanimously resolved to approve the Transaction. Skadden, Arps, Slate, Meagher & Flom LLP acted as legal advisor to Vertex Pharmaceuticals.

Negative

Vertex Pharmaceuticals Incorporated Elects Suketu Upadhyay as Independent Director

2022-05-18 14:30:00

Vertex Pharmaceuticals Incorporated announced that Suketu Upadhyay elected to its board of directors as an independent director. Upadhyay is a global business executive with more than 20 years of experience in the pharmaceutical and medical technology sectors, serving in financial and strategy roles covering multiple areas of the life sciences sector. He is currently the Executive Vice President and Chief Financial Officer of Zimmer Biomet, a position he has held since July 2019.

Positive

Vertex Pharmaceuticals Incorporated Announces Further Expansion in the Boston Seaport At Dedication of the Jeffrey Leiden Center for Cell and Genetic Therapies

2022-05-17 10:45:00

Vertex Pharmaceuticals Incorporated announced plans to build another 344,000 square foot facility in the Seaport to support the company’s continued rapid growth, in particular the expansion of its cell and genetic therapies programs. With the completion of this new site expected in 2025, Vertex will occupy 1.9 million square feet of real estate in the Seaport across five sites, making it the biotech in Boston in terms of square footage. Vertex dedicated its site at 316-318 Northern Avenue in honor of the company’s Executive Chairman and Former CEO, Jeffrey Leiden, M.D., Ph.D. Leiden I is anew state-of-the-art cell and genetic therapies research and clinical manufacturing site, which accommodates more than 400 employees, with 70% of the facility dedicated to lab and research space. Cell and genetic therapies are two rapidly emerging therapeutic modalities with the potential to treat the underlying cause — and even cure — several of the serious diseases Vertex is working on including sickle cell disease, beta thalassemia, type 1 diabetes and Duchenne muscular dystrophy. The further expansion, being developed in partnership with Related Beal, Boston Real Estate Inclusion Fund and Kavanagh Advisory group, is anew 344,000 square foot facility located at 20-22 Drydock Avenue. Once this facility is complete, the two buildings will be known as the Leiden Campus and will help support the company’s continued growth in multiple disease areas, spanning multiple modalities and further enable its research and development teams to bring transformative therapies to patients. The new building will house labs, offices and manufacturing capabilities for approximately 500 additional employees.

Neutral

Vertex Pharmaceuticals Incorporated Reiterates Earning Guidance for 2022

2022-05-05 20:01:00

Vertex Pharmaceuticals Incorporated reiterated earning guidance for 2022. The Company expects product revenue guidance of $8.4 to $8.6 billion.

Positive

Vertex Pharmaceuticals Incorporated Provides Updates on Phase 1/2 Clinical Trial of Vx-880 for the Treatment of Type 1 Diabetes

2022-05-02 12:30:00

--Vertex Pharmaceuticals Incorporated provided updates on its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemia. Two patients in Part A received VX- 880 at half the target dose. The first patient dosed in Part A of the study achieved insulin independence at Day 270, with a HbA1c of 5.2%. The second patient dosed in Part A has shown robust increases in fasting and stimulated C-peptide, and reductions in exogenous insulin requirements through Day 150. Taken together, the data from the first two patients in Part A established proof-of-concept for VX-880. Per the study protocol, the Independent Data Monitoring Committee reviewed the totality of the safety and efficacy data from the first two patients dosed in Part A of the study andrecommended advancement to Part B, where patients receive the full target dose of VX-880. The first patient to receive the full target dose has achieved the Day 29 follow-up milestone. Across the program, VX-880 has been generally well tolerated to date. There have been no serious adverse events (SAEs) considered related to VX-880. The majority of adverse events (AEs) were mild or moderate in all patients treated to date. The safety profile was generally consistent with the immunosuppressive regimen used in the study and the perioperative period. The company also announced the VX-880 Phase 1/2 study has been placed on clinical hold in the U.S. by the Food and Drug Administration (FDA) due to a determination that there is insufficient information to support dose escalation with the product. Safety and Efficacy Results To date, three patients have been dosed in the Phase 1/2 study with VX-880. Two patients received half the target dose of cells in Part A of the study. A third patient has received the full target dose in Part B of the study. Patient 1 Results from Day 90 and Day 150 were previously reported. The patient achieved insulin independence at Day 270 with a HbA1c level of 5.2%. The study protocol defines insulin independence as no exogenous insulin use for at least one week,HbA1c <= 7%, fasting serum glucose <=126 mg/dL, post-prandial serum glucose of <=180 mg/dL, and fasting or stimulated C- peptide >=166 pmol/L. Through Day 270, there were no SAEs considered related to VX-880. There were two SAEs, one of rash and one of dehydration, neither of which were considered related to VX--880. The majority of the AEs were considered mild to moderate. The most common AEs were severe hypoglycemic events, which were not related to VX-880, and occurred in the perioperative period. Patient 2 Islet cell function was evaluated at baseline and at Day 90 after VX-880 infusion using a Mixed Meal Tolerance Test (MMTT) with quantification of C-peptide levels, a direct marker for endogenous insulin production. At baseline prior to VX-880 infusion, fasting and stimulated C-peptide levels were undetectable, indicating no endogenous insulin production. At Day 90, stimulated C-peptide increased to a peak of 202 pmol/L, indicating that VX-880 restored glucose-responsive insulin production. At Day 150, HbA1c decreased to 7.1% compared to a baseline of 7.5%, and exogenous insulin use decreased by 30%. Through Day 150, there were no SAEs, and all AEs were considered mild to moderate. The most common AEs were headache and hypomagnesemia, which were not considered related to VX-880. Patient 3 The third patient received the full target dose of VX-880 and has reached the Day 29 follow-u visit. Early data show increasing fasting C-peptide and improving glycemic control through Day 29. Comprehensive evaluation of islet cell function will be evaluated based on the MMTT during the Day 90 visit. Through Day 29, there were no SAEs considered related to VX-880. The patient had one SAE of neutropenia, which was not considered related to VX-880. The majority of the AEs were considered mild to moderate. The most common AE was nausea, which was not considered related to VX-880. Cells Plus Device ProgramVertex is also pursuing additional programs in T1D, including one in which these same stem cell-derived islets are encapsulated in an immunoprotective device to be surgically implanted without the use of concomitant immunosuppression,and another program where cells are modified to produce hypoimmune stem cell-derived islets. IND-enabling studies for the encapsulated cells program are underway, and the company remains on track to submit an IND in 2022.

Neutral

Vertex Pharmaceuticals Incorporated, Q1 2022 Earnings Call, May 05, 2022

2022-04-21 20:05:00

Vertex Pharmaceuticals Incorporated, Q1 2022 Earnings Call, May 05, 2022

Neutral

Vertex Pharmaceuticals Incorporated to Report Q1, 2022 Results on May 05, 2022

2022-04-21 20:05:00

Vertex Pharmaceuticals Incorporated announced that they will report Q1, 2022 results After-Market on May 05, 2022

Positive

Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Marketing Authorization for TRIKAFTA in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation

2022-04-20 21:45:00

Vertex Pharmaceuticals Incorporated announced that Health Canada has granted Marketing Authorization for the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include children with cystic fibrosis (CF) ages 6 through 11 years who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. With this announcement, approximately 500 Canadians with CF ages 6-11 are now eligible for TRIKAFTA®. As a result of this approval, an additional dosage strength of TRIKAFTA® tablets is now available (elexacaftor 50 mg/tezacaftor 25 mg/ivacaftor 37.5 mg and ivacaftor 75 mg). Vertex completed a 24-week Phase 3 open-label, multicenter study which enrolled 66 children ages 6 through 11 years old with CF who have either two copies of the F508del mutation or one copy of the F508del mutation and one minimal function mutation to evaluate the safety, pharmacokinetics and efficacy of TRIKAFTA®. The regimen was generally well tolerated, and safety data were consistent with those observed in previous studies in patients ages 12 years and older. Vertex has also submitted this indication to both the Canadian Agency for Drugs and Technologies in Health (CADTH) and the Institut national d'excellence en santé et en services sociaux (INESSS) in Québec for Health Technology Assessments. Cystic fibrosis is a progressive, multi-organ disease that affects the lungs, liver, pancreas, GI tract, sinuses, sweat glands and reproductive tract. CF is caused by a defective and/or missing CFTR protein resulting from certain mutations in the CFTR gene. Children must inherit two defective CFTR genes – one from each parent – to have CF, and these mutations can be identified by a genetic test. While there are many different types of CFTR mutations that can cause the disease, the vast majority of people with CF have at least one F508del mutation. CFTR mutations lead to CF by causing CFTR protein to be defective or by leading to a shortage or absence of CFTR protein at the cell surface. The defective function and/or absence of CFTR protein results in poor flow of salt and water into and out of the cells in a number of organs. In the lungs, this leads to the buildup of abnormally thick, sticky mucus, chronic lung infections and progressive lung damage that eventually leads to death for many patients. The median age of death is in the early 30s. In people with certain types of mutations in the CFTR gene, the CFTR protein is not processed or folded normally within the cell, and this can prevent the CFTR protein from reaching the cell surface and functioning properly. TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) is an oral medicine designed to increase the quantity and function of the CFTR protein at the cell surface. Elexacaftor and tezacaftor work together to increase the amount of mature protein at the cell surface by binding to different sites on the CFTR protein. Ivacaftor, which is known as a CFTR potentiator, is designed to facilitate the ability of CFTR proteins to transport salt and water across the cell membrane. The combined actions of elexacaftor, tezacaftor and ivacaftor help hydrate and clear mucus from the airways. TRIKAFTA® is a prescription medicine used for the treatment of cystic fibrosis (CF) in patients ages 6 years and older who have at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Neutral

Vertex Pharmaceuticals Incorporated - Shareholder/Analyst Call

2022-04-07 20:06:00

AGM

Neutral

Vertex Pharmaceuticals Incorporated, Annual General Meeting, May 18, 2022

2022-04-07 20:06:00

Vertex Pharmaceuticals Incorporated, Annual General Meeting, May 18, 2022, at 09:30 US Eastern Standard Time. Agenda: To elect the 11 director nominees that are set forth in the attached proxy statement to board of directors to serve for a one-year term until the 2023 annual meeting of shareholders and until his or her successor has been duly elected and qualified; to ratify the selection of Ernst & Young LLP as independent registered public accounting firm for 2022; to approve 2021 named executive officer compensation in an advisory vote; and to consider other matters.

Positive

Vertex Pharmaceuticals Incorporated Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain

2022-03-31 12:00:00

Vertex Pharmaceuticals Incorporated announced positive results from two Phase 2 proof-of-concept (POC) studies that investigated treatment with the selective NaV1.8 inhibitor VX-548 for acute pain following abdominoplasty surgery or bunionectomy surgery. Treatment with an initial dose of 100 mg followed by 50 mg every 12 hours of VX-548 (high-dose) compared to placebo resulted in a rapid, statistically significant and clinically meaningful improvement in the primary endpoint of the time-weighted Sum of Pain Intensity Difference over 48 hours (SPID48), which was consistent in both trials. The study also included an active reference arm of the opioid hydrocodone bitartrate/acetaminophen (HB/APAP) to support the evaluation of the VX-548 treatment effect. VX-548 was generally well tolerated in both studies. Most adverse events (AEs) were mild to moderate and there were no serious adverse events (SAEs) related to VX-548. Fewer patients discontinued treatment in the mid- and high-dose VX-548 arms than in the placebo group or HB/APAP reference arm. Based on these positive proof-of-concept efficacy results, and the safety and tolerability profile across both the abdominoplasty and bunionectomy studies, Vertex plans to advance VX-548 into pivotal development in the second half of 2022, following discussions with regulators. 548 Results in Patients Undergoing Bunionectomy: Efficacy Results: The bunionectomy study met its primary endpoint, showing a statistically significant improvement in SPID48, as recorded on a Numeric Pain Rating Scale (NPRS), for those treated with VX-548 at the high dose compared to placebo. Higher SPID48 values represent greater improvements in pain relief. The onset of action was rapid and was sustained through the duration of assessment. Safety Results: VX-548 was generally well tolerated in this study. Discontinuation rates, including discontinuations due to lack of efficacy, were lower in the VX-548-treated mid- and high-dose arms than in the placebo group or HB/APAP reference arm. No patients discontinued treatment due to AEs and no patients had SAEs. All AEs were mild or moderate. The most common AEs (incidence >10% in either placebo, HB/APAP or VX-548 high-dose group, respectively) were headache (12%, 7%, 8%) and nausea (9%, 18%, 8%). VX-548 Results in Patients Undergoing Abdominoplasty: Efficacy Results: The abdominoplasty study met its primary endpoint, showing a statistically significant improvement in SPID48, as recorded on a NPRS, for those treated with VX-548 at the high dose compared to placebo. Similar to pain relief in the bunionectomy study, the onset of action was rapid and was sustained through the assessment period. Safety Results: VX-548 was generally well tolerated in this study. Discontinuation rates, including discontinuations due to lack of efficacy, were lower in the VX-548-treated arms than in the placebo group or HB/APAP reference arm. Two patients in the mid-dose VX-548 arm discontinued treatment due to AEs, none of which were related to treatment. There were three patients who experienced SAEs: one patient in the placebo arm, one patient in the HB/APAP arm, and one patient in the VX-548 mid-dose treatment arm, none of which were related to treatment. The majority of AEs were mild or moderate. The most common AEs (incidence >10% in either placebo, HB/APAP or high-dose VX-548 group, respectively) were nausea (36%, 30%, 18%), headache (7%, 7%, 15%), constipation (5%, 12%, 9%), dizziness (18%, 11%, 8%) and vomiting (7%, 11%, 3%). Next Steps: As a result of these positive data, Vertex plans to advance VX-548 into pivotal development in the second half of 2022, following discussions with regulators. The full data set from these studies will be presented at a future medical meeting.

Neutral

American Kidney Fund Announces Support from Vertex Pharmaceuticals Inc. to Raise Awareness and Increase Education of the APOL1 Gene and Its Link to Kidney Disease

2022-03-29 13:00:00

The American Kidney Fund (AKF) announced that Vertex Pharmaceuticals Inc. is providing support for AKF’s education and awareness campaign about the apolipoprotein L1 (APOL1) gene and its link to kidney disease in people of African and Caribbean descent. While every person has the APOL1 gene, variants of the gene are connected to higher rates of severe kidney disease in people of African and Caribbean descent. For example, people diagnosed with focal segmental glomerulosclerosis (FSGS)—a rare kidney disease that causes scarring on the kidneys’ filters—are 17 times more likely to have the APOL1 genetic variant. Through this new campaign, AKF and Vertex aim to increase awareness and education about the connection between APOL1 and kidney disease and the need for increased genetic testing. For the campaign, AKF will develop an APOL1 “brain trust” consisting of a group of people with kidney disease attributed to the APOL1 variant and a health care professional expert on the subject. Through individual interviews, the brain trust will inform the campaign’s strategies and tactics to ensure education gaps are being adequately addressed. Patient-facing resources that will be developed as a result of the brain trust’s findings will include digital engagement tools, including how to find a genetic counselor, and a dedicated webpage with enhanced educational materials and a patient experience video series. Because APOL1 as a potential genetic marker for kidney disease remains a topic new to many health care professionals, AKF’s campaign will also educate them about the role of variants in kidney genetics and their potential impact on people of color via a professional-facing webinar and education materials.

Neutral

Vertex Pharmaceuticals Incorporated Presents at Pharma Manufacturing World Summit, Mar-29-2022

2022-03-29 08:36:00

Vertex Pharmaceuticals Incorporated Presents at Pharma Manufacturing World Summit, Mar-29-2022 . Venue: Boston Marriott Copley Place, Boston, Massachusetts, United States. Speakers: E. Morrey Atkinson, SVP and Head of Commercial Manufacturing and Supply Chain.

Neutral

Executive Platforms Inc., Pharma Manufacturing World Summit, Mar 29, 2022 through Mar 30, 2022

2022-03-21 14:57:00

Executive Platforms Inc., Pharma Manufacturing World Summit, Mar 29, 2022 through Mar 30, 2022. Venue: Boston Marriott Copley Place, Boston, Massachusetts, United States.

Neutral

American Diabetes Association, Inc., 82nd Scientific Sessions of the American Diabetes Association conference, Jun 03, 2022 through Jun 07, 2022

2022-03-16 13:54:00

American Diabetes Association, Inc., 82nd Scientific Sessions of the American Diabetes Association conference, Jun 03, 2022 through Jun 07, 2022. Venue: New Orleans, Louisiana, United States.

Positive

Vertex Pharmaceuticals Seeks Acquisitions

2022-02-09 21:46:00

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) is looking for acquisitions. The company said "We expect to continue to identify and evaluate potential acquisitions and may include larger transactions or later-stage assets".

Neutral

Tranche Update on Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX)'s Equity Buyback Plan announced on June 24, 2021.

2022-02-09 16:38:00

From October 1, 2021 to December 31, 2021, the company has repurchased 1,986,042 shares, representing 0.78% for $358.14 million. With this, the company has completed the repurchase of 5,279,203 shares, representing 2.05% for $1,000.34 million under the buyback announced on June 24, 2021.

Neutral

Vertex Pharmaceuticals Incorporated has filed a Shelf Registration.

2022-02-09 00:00:00

Vertex Pharmaceuticals Incorporated has filed a Shelf Registration. Security Name: Common Stock Security Name: Debt Securities Security Name: Preferred Stock Security Name: Warrants Security Name: Subscription Rights Security Name: Purchase Contracts Security Name: Purchase Units Transaction Features: Omnibus/Universal Shelf Registration

Neutral

The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022

2022-02-08 07:31:00

The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022. Venue: Terranea Resort, Rancho Palos Verdes, California, United States.

Neutral

Vertex Pharmaceuticals Incorporated - Special Call

2021-12-01 12:37:00

To discuss the positive results from Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis

Positive

Vertex Pharmaceuticals Incorporated Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis

2021-12-01 12:30:00

Vertex Pharmaceuticals Incorporated announced that, in a Phase 2 proof-of-concept (POC) study in patients with APOL1-mediated focal segmental glomerulosclerosis (FSGS), VX-147 on top of standard of care achieved a statistically significant, substantial and clinically meaningful mean reduction of 47.6% in the urine protein to creatinine ratio (UPCR) at Week 13 compared to baseline. VX-147 was well tolerated. These results provide the first clinical evidence and POC that an oral small molecule APOL1 inhibitor can decrease proteinuria in patients with APOL1-mediated kidney disease. Based on these results, Vertex plans to advance VX-147 into pivotal development in APOL1-mediated kidney disease, including FSGS, in First Quarter 2022. A total of 16 patients were enrolled in the study. According to the pre-specified statistical analysis plan, three patients who were noncompliant with treatment were not included in the primary efficacy analysis. In the 13 evaluable patients, treatment with VX-147 on top of standard of care resulted in a rapid, statistically significant and clinically meaningful mean change in proteinuria from baseline of -47.6% (95% CI: -60.0%, -31.3%) following 13 weeks of treatment. Reduction in proteinuria was observed early and continued throughout the 13-week treatment period. Results were consistent regardless of baseline proteinuria or background therapy. There were no treatment discontinuations due to adverse events (AEs), and there were no serious adverse events considered related to study drug. All AEs were mild or moderate in severity. The most common AEs (occurring in > 15% of subjects) were headache, back pain and nausea. About the VX-147 Phase 2 Study: The Phase 2 open-label, single-arm study evaluated the efficacy, safety and pharmacokinetics of VX-147 in patients with APOL1-mediated FSGS. Patients with biopsy-confirmed FSGS, two APOL1 genetic variants, proteinuria defined by at least 0.7 g/g in the UPCR and an estimated glomerular filtration rate (eGFR) of at least 27 mL/min/1.73 m2 were eligible for enrollment in the study. Patients were on a stable standard-of-care regimen, which could include an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin II receptor blocker (ARB), immunosuppressants and/or low doses of corticosteroids. Patients were treated with VX-147 for a total of 13 weeks. The primary endpoint was percent change from baseline in UPCR at Week 13. The secondary endpoints were safety and pharmacokinetics. In addition, there is a 28-day safety follow-up period after the last dose of treatment and an optional off-treatment follow-up period of up to 12 weeks after the last dose of treatment. The study is ongoing for these follow-up periods. About APOL1-Mediated Kidney Disease: APOL1-mediated kidney disease is a form of chronic kidney disease caused by variants of the APOL1 gene. Over 100,000 people in the U.S. and Europe have two APOL1 genetic variants and proteinuric kidney disease. People who inherit two risk variants in the APOL1 gene have a course of disease that is far more aggressive than in the absence of APOL1 genetic variants. Inherited APOL1 genetic variants cause kidney disease through a toxic gain of function, which leads to podocyte injury. This injury disrupts filtration, resulting in proteinuria and rapidly progressive kidney disease. Progressive kidney disease can result in dialysis, kidney transplant or death.

Positive

Vertex Pharmaceuticals Incorporated Receives CHMP Positive Opinion for Kaftrio(Ivacaftor/Tezacaftor/Elexacaftor) in Combination with Ivacaftor in Children with Cystic Fibrosis Ages 6 Through 11

2021-11-12 12:27:00

Vertex Pharmaceuticals Incorporated announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the label extension of KAFTRIO (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor, for the treatment of cystic fibrosis (CF) in patients ages 6 through 11 years old who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Positive

Arbor Biotechnologies, Inc. announced that it has received $214.999959 million in funding from a group of investors

2021-11-09 00:00:00

On November 9, 2021, Arbor Biotechnologies, Inc. closed the transaction. The transaction was led by new investors Temasek Holdings (Private) Limited, Ally Bridge Group, and TCG Crossover Management, LLC The transaction also included participation from other new investors Tekla Capital Management LLC, T. Rowe Price Group, Inc., Ridgeback Capital Management, LLC, Greatpoint Investment Management, LLC, Logos Capital Management, LLC, ArrowMark Colorado Holdings, LLC, Tao Capital Partners, IIF Management Company, LLC, Section 32, LLC, Janus Henderson Group plc, Woodline Partners LP, Piper Heartland Healthcare Capital, LLC, Deep Track Capital, LP, Ono Venture Investment, Citadel Multi-Strategy Equities Master Fund Ltd.; a fund managed by Citadel Advisors LLC, Vertex Pharmaceuticals Incorporated, and existing investors Arch Venture Partners, L.P., and an undisclosed global investment firm. The company raised $300,000,000 in funding till date. Chen Yu of TCG Crossover Management will join the company's Board of Directors. The round was oversubscribed. The company has raised $214,999,926 through Regulation D in the transaction. The transaction included participation from total 37 investors.

Neutral

Tranche Update on Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX)'s Equity Buyback Plan announced on June 24, 2021.

2021-11-03 16:18:00

From July 1, 2021 to September 30, 2021, the company has repurchased 3,293,161 shares, representing 1.27% for $642.2 million. With this, the company has completed the repurchase of 3,293,161 shares, representing 1.27% for $642.2 million under the buyback announced on June 24, 2021.

Positive

Vertex Pharmaceuticals Incorporated Revises Revenue Guidance for the Year 2021

2021-11-02 20:01:00

Vertex Pharmaceuticals Incorporated raised full-year 2021 product revenue guidance to $7.4 to $7.5 billion compared to previous guidance of $7.2 to $7.4 billion.

Positive

Arbor Biotechnologies, Inc. announced that it expects to receive $214.999926 million in funding

2021-10-29 00:00:00

Arbor Biotechnologies, Inc. announced that it will issue 12,975,254 series B preferred shares at a price of $16.57 per share for gross proceeds of $214,999,958.78 on October 29, 2021. The shares are convertible and non-cumulative. The shares carry non-cumulative fixed dividend rate of 8% per annum. The shares are convertible into common shares of the company at a fixed conversion price of $16.57 per share. The transaction is being raised at a post-money valuation of $456,161,843.The company will receive $214,999,926 in funding pursuant to exemption provided under Regulation D.

Neutral

Ginkgo Bioworks Holdings, Inc., Annual Ferment Conference, Oct 28, 2021

2021-10-28 12:00:00

Ginkgo Bioworks Holdings, Inc., Annual Ferment Conference, Oct 28, 2021.

Neutral

Vertex Pharmaceuticals Incorporated Presents at Annual Ferment Conference, Oct-28-2021

2021-10-28 12:00:00

Vertex Pharmaceuticals Incorporated Presents at Annual Ferment Conference, Oct-28-2021 . Speakers: Reshma Kewalramani, CEO, President & Director.

Positive

Vertex Pharmaceuticals Incorporated's Supplement to a New Drug Submission for TRIKAFTA® in Patients Ages 6-11 Accept for Priority Review by Health Canada

2021-10-27 16:07:00

Vertex Pharmaceuticals Incorporated announced that its Supplement to a New Drug Submission for PrTRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) has been accepted for Priority Review by Health Canada for the treatment of cystic fibrosis (CF) in people ages 6-11 years. Vertex will also submit this indication in parallel to both the Canadian Agency for Drugs and Technologies in Health (CADTH) and the Institut national d'excellence en santé et en services sociaux (INESSS) in Quebec for Health Technology Assessments.

Positive

Vertex and Mammoth Biosciences Announce Collaboration to Develop in Vivo Gene-Editing Therapies for Serious Diseases

2021-10-26 13:00:00

Vertex Pharmaceuticals Incorporated and Mammoth Biosciences, Inc. announced a new partnership to develop in vivo gene-editing therapies for two genetic diseases using Mammoth’s next-generation CRISPR systems. Driven by its unique protein discovery engine, Mammoth’s CRISPR platform consists of a proprietary toolbox of novel, ultracompact Cas enzymes, including Cas14 and CasÉ. The small size of these Mammoth systems, together with further optimized parameters, have the potential to facilitate advanced delivery, which may increase the scope of in vivo gene-editing for genetic diseases.

Neutral

Vertex Pharmaceuticals Incorporated, Q3 2021 Earnings Call, Nov 02, 2021

2021-10-22 12:00:00

Vertex Pharmaceuticals Incorporated, Q3 2021 Earnings Call, Nov 02, 2021

Neutral

Vertex Pharmaceuticals Incorporated to Report Q3, 2021 Results on Nov 02, 2021

2021-10-22 12:00:00

Vertex Pharmaceuticals Incorporated announced that they will report Q3, 2021 results After-Market on Nov 02, 2021

Positive

Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North American Cystic Fibrosis Conference (NACFC)

2021-10-19 12:00:00

Vertex Pharmaceuticals Incorporated announced that five scientific abstracts about the company’s portfolio of cystic fibrosis (CF) medicines will be presented at the 2021 North American Cystic Fibrosis Conference (NACFC) taking place virtually November 2-5, 2021. Key data being presented include 96-week interim results from an ongoing TRIKAFTA® open-label extension study in people with CF ages 12 years and older with F508del/Minimal Function (F/MF) or F508del/F508del (F/F) genotypes, showing that the favorable safety profile and clinically meaningful improvements in lung function, respiratory symptoms and CFTR function as measured by sweat chloride observed in the Phase 3 pivotal studies were maintained through an additional 96 weeks of treatment (Poster #681). Additionally, a post hoc analysis of the annualized mean rate of change in % predicted forced expiratory volume in 1 second (ppFEV1) showed there was no loss of pulmonary function over 96 weeks in this CF population, which is a first for any CFTR modulator to date. Also presented at this year’s conference are data on results from a retrospective study of patients with gating mutations ages 6 years or older treated with KALYDECO® showing that people treated with KALYDECO® over approximately six years of follow up had significantly lower rates of mortality, lung transplant and pulmonary exacerbations (PEx) compared to a cohort of patients that were not eligible for and not receiving KALYDECO treatment (Poster #178). In addition to the studies noted above, other presentations at NACFC include: INTERIM RESULTS FROM THE HELIO STUDY: Interim analysis of a study of the real-world clinical effectiveness of TRIKAFTA® in people with CF age 12 years and older with at least one F508del allele who were ineligible for another CFTR modulator, demonstrating clinically meaningful improvements in lung function and nutritional status at 6 months. In addition, the annualized PEx rate was lower with TRIKAFTA treatment. These results are consistent with findings from pivotal clinical trials. QUALITATIVE STUDY OF PATIENTS TREATED WITH TRIKAFTA AND CAREGIVERS: Results from an ongoing qualitative study to evaluate (1) the real-world patient experience of TRIKAFTA® treatment from the perspective of people with CF and caregivers and (2) the impact of TRIKAFTA® on the caregiver experience. The impact of the SARS-CoV-2 pandemic was also included in the assessment of the patient and caregiver experience. Results from this study demonstrate that TRIKAFTA® has a meaningful and substantial impact on the daily lives of people with CF and caregivers, including the ability to cope with living through the SARS-CoV-2 pandemic. INTERIM RESULTS FROM A PHASE 3 OPEN-LABEL EXTENSION STUDY OF CHILDREN WITH CF AGES 6 YEARS AND OLDER: An interim analysis at week 24 of an ongoing, 96-week, Phase 3, open-label extension study designed to assess the long-term safety and efficacy of TRIKAFTA® in children 6 years of age and older with at least one F508del allele. Results were consistent with the previously established safety profile of TRIKAFTA®in this age group. Results also showed robust and clinically meaningful improvements in lung function, respiratory symptoms, and CFTR activity as measured by sweat chloride and indicate TRIKAFTA® provides long-term benefit in this younger patient population.

Neutral

Molecular Templates, Inc. Receives Notice from Vertex Pharmaceuticals Incorporated to Terminate the Company's Master Collaboration Agreement

2021-10-18 11:31:00

On October 15, 2021, Molecular Templates Inc. received notice from Vertex Pharmaceuticals Incorporated (Vertex") that Vertex has decided to terminate the Company's Master Collaboration Agreement by and between the Company and Vertex, dated November 18, 2019 (the Collaboration Agreement"), a research collaboration which the Company and Vertex entered into focused on developing conditioning agents for applications outside of oncology. The termination of the Collaboration Agreement will be effective on October 29, 2021. In this collaboration, the Company was developing engineered toxin bodies for myeloablation, an indication separate from the Company's core focus on cancer therapeutics. Pursuant to the terms of the Collaboration Agreement, Vertex paid the Company an upfront payment of $38.0 million, which included proceeds from a concurrent equity investment. In addition to the upfront payments, under the Collaboration Agreement, the Company had the opportunity to receive an additional $22.5 million through the exercise by Vertex of the options to license engineered toxin body products or to add an additional target. The Company also had the opportunity, for each target under the Collaboration Agreement, to receive up to an additional $180.0 million in milestone payments upon the achievement of certain development and regulatory milestone events and up to an additional $70.0 million in milestone payments upon the achievement of certain sales milestone events. The Company also had the opportunity to receive, subject to certain reductions, tiered mid-single digit royalties as percentages of calendar year net sales, if any, on any licensed product under the Collaboration Agreement.

Positive

Vertex Pharmaceuticals Incorporated Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes

2021-10-18 11:30:00

Vertex Pharmaceuticals Incorporated announced positive Day 90 data for the first patient from the Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D). This is the first demonstration of a patient with T1D achieving robust restoration of islet cell function from such a cell therapy. The patient was treated with a single infusion of VX-880 at half the target dose in conjunction with immunosuppressive therapy. The patient achieved successful engraftment and demonstrated rapid and robust improvements in multiple measures, including increases in fasting and stimulated C-peptide, improvements in glycemic control, including HbA1c, and decreases in exogenous insulin requirement. VX-880 was generally well tolerated. The patient was diagnosed with T1D approximately 40 years ago and has been dependent on exogenous insulin. In the one year prior to treatment, the patient experienced 5 severe, potentially life-threatening hypoglycemic episodes. Prior to treatment with VX-880, the patient’s insulin dose was 34 units per day and fasting and stimulated C-peptide levels were undetectable, indicating that the patient was not making their own insulin. Per the study protocol, the patient received half the target dose of VX-880 through a hepatic portal vein infusion in combination with a standard regimen of immunosuppressive agents. Fasting C-peptide, HbA1c and 7-day average daily insulin dose were measured at various intervals after VX-880 treatment through Day 90. Fasting C-peptide was detected early after treatment with VX-880 and increased rapidly to Day 90. In parallel, HbA1c and daily insulin dose decreased over time. Islet cell function was evaluated at baseline and at Day 90 using a Mixed Meal Tolerance Test (MMTT) with quantification of C-peptide levels, a direct marker for insulin production. At baseline prior to VX-880 treatment, fasting and stimulated C-peptide levels were undetectable, indicating no endogenous insulin production. At Day 90 after VX-880 treatment, fasting C-peptide was 280 pmol/L, reflecting restored basal insulin production and increased after MMTT stimulation to a peak of 560 pmol/L, indicating that VX-880 restored glucose-responsive insulin production. Also at Day 90, HbA1c improved from 8.6% at baseline to 7.2%, and daily insulin dose decreased from 34 units per day prior to treatment with VX-880 to an average dose of 2.9 units per day over a 7-day period at the Day 90 visit, reflecting a 91% decrease in daily exogenous insulin use. In this first patient, the safety of VX-880 was generally consistent with the immunosuppressive regimen used in this study. There were no serious adverse events (SAE) considered related to VX-880, and the majority of the adverse events were considered mild to moderate. The most common adverse events were severe hypoglycemic events, which were non-serious, not related to VX-880, and occurred in the perioperative period. Through Day 90, the patient had one SAE; this was a rash that was mild in severity, not related to VX-880, and resolved. Based upon these data, Vertex plans to continue to progress the Phase 1/2 program for VX-880. There are multiple active sites in the U.S., and the Clinical Trial Application has been approved in Canada. Vertex is also progressing IND-enabling studies for its encapsulated islet cell program, which would potentially eliminate the requirement for immunosuppression, and plans to file an IND for this program in 2022. VX-880 is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy manufactured using proprietary technology. VX-880 is being evaluated for patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. VX-880 has the potential to restore the body’s ability to regulate glucose levels by restoring pancreatic islet cell function, including glucose responsive insulin production. VX-880 is delivered by an infusion into the hepatic portal vein and requires chronic immunosuppressive therapy to protect the islet cells from immune rejection. The clinical trial is a Phase 1/2, multi-center, single-arm, open-label study in patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. This study is designed as a sequential, multi-part clinical trial to evaluate the safety and efficacy of VX-880. The first two patients will be treated with half the target dose, followed by dose escalation to the target dose in the subsequent patients. Approximately 17 patients will be enrolled in the clinical trial. Enrollment is ongoing in this study. T1D results from the autoimmune destruction of insulin-producing islet cells in the pancreas, leading to loss of insulin production and impairment of blood glucose control. The absence of insulin leads to abnormalities in how the body processes nutrients, leading to high blood glucose levels. High blood glucose can lead to diabetic ketoacidosis and over time, to complications such as kidney disease/failure, eye disease (including vision loss), heart disease, stroke, nerve damage and even death. Due to the limitations and complexities of insulin delivery systems, it can be difficult to achieve and maintain balance in glucose control in patients with T1D. Hypoglycemia often results because of the difficulty in balancing the different factors that impact glucose levels, including insulin, diet and exercise. Hypoglycemia remains a critical limiting factor in glycemic management, and severe hypoglycemia can cause loss of consciousness, coma, seizures, injury, and can be fatal. Over time, patients with T1D can develop impaired awareness of hypoglycemia, meaning they are no longer able to perceive the early signs of a hypoglycemic event, which can be dangerous and result in life threatening events. Current standards of care do not address the underlying causes of the disease, and there are limited treatment options beyond insulin for the management of T1D.

Neutral

Vertex Pharmaceuticals Incorporated Presents at Cell & Gene Meeting on the Mesa, Oct-12-2021

2021-09-30 22:23:00

Vertex Pharmaceuticals Incorporated Presents at Cell & Gene Meeting on the Mesa, Oct-12-2021 . Venue: Carlsbad, California, United States.

Neutral

Vertex Pharmaceuticals Incorporated Presents at Transparency & Aggregate Spend, Dec-06-2021 through Dec-10-2021

2021-09-28 14:33:00

Vertex Pharmaceuticals Incorporated Presents at Transparency & Aggregate Spend, Dec-06-2021 through Dec-10-2021. Venue: Hilton Philadelphia at Penn's Landing, Philadelphia, Pennsylvania, United States. Presentation Date & Speakers: Dec-06-2021, Jeffrey Carter, Manager, Global Spend Transparency. Dec-07-2021, Giulia Bolzonello, Manager, Global Spend Transparency.

Neutral

Informa plc, Transparency & Aggregate Spend, Dec 06, 2021 through Dec 10, 2021

2021-09-27 17:31:00

Informa plc, Transparency & Aggregate Spend, Dec 06, 2021 through Dec 10, 2021. Venue: Hilton Philadelphia at Penn's Landing, Philadelphia, Pennsylvania, United States.

Positive

Vertex Pharmaceuticals Incorporated Announces Its Supplement to a New Drug Submission for PrKALYDECO

2021-09-22 15:16:00

Vertex Pharmaceuticals Incorporated announced its Supplement to a New Drug Submission for PrKALYDECO® (ivacaftor) has been accepted for priority review by Health Canada for the treatment of cystic fibrosis (CF) in patients from 4 months to 18 years of age and weighing at least 5 kg with the R117H mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Positive

Vertex Pharmaceuticals Incorporated Letter of Intent with Pan-Canadian Pharmaceutical Alliance for Public Reimbursement of CFTR Modulators Extended to Include TRIKAFTA®(elexacaftor/tezacaftor/ivacaftor and ivacaftor)

2021-09-17 20:19:00

Vertex Pharmaceuticals Incorporated (Canada) announced that it has signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA), which represents an agreement in principle regarding the public reimbursement of PrTRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for eligible patients with cystic fibrosis (CF). This is an extension of the LOI with the pCPA including PrKALYDECO® (ivacaftor) and PrORKAMBI® (lumacaftor/ivacaftor).This extension of the LOI follows the positive clinical recommendation for TRIKAFTA® by both the Canadian Agency for Drugs and Technology in Health (CADTH) and l'Institut national d'excellence en santé et en services sociaux (INESSS) in Quebec. TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) is a prescription medicine used for the treatment of cystic fibrosis (CF) in patients ages 12 years and older who have at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. TRIKAFTA® is designed to increase the quantity and function of the F508del-CFTR protein at the cell surface. The approval of TRIKAFTA® was supported by positive results of three global Phase 3 studies in people ages 12 years and older with CF: a 24-week Phase 3 study (Study 445-102) in 403 people with one F508del mutation and one minimal function mutation (F/MF), a four-week Phase 3 study (Study 445-103) in 107 people with two F508del mutations (F/F), and a Phase 3 study (Study 445-104) in 258 people heterozygous for the F508del-CFTR mutation and a CFTR gating mutation (F/G) or a residual function mutation (F/RF). Cystic fibrosis (CF) is a rare, life-shortening genetic disease affecting more than 80,000 people globally. CF is a progressive, multi-system disease that affects the lungs, liver, GI tract, sinuses, sweat glands, pancreas and reproductive tract. CF is caused by a defective and/or missing CFTR protein resulting from certain mutations in the CFTR gene. Children must inherit two defective CFTR genes — one from each parent — to have CF. While there are many different types of CFTR mutations that can cause the disease, the vast majority of all people with CF have at least one F508del mutation. These mutations, which can be determined by a genetic test, or genotyping test, lead to CF by creating non-working and/or too few CFTR proteins at the cell surface. The defective function and/or absence of CFTR protein results in poor flow of salt and water into and out of the cells in a number of organs. In the lungs, this leads to the buildup of abnormally thick, sticky mucus that can cause chronic lung infections and progressive lung damage in many patients that eventually leads to death. The median age of death is in the early 30s.

Neutral

Vertex Pharmaceuticals Incorporated Presents at Cell & Gene Therapy Bioprocessing & Commercialization, Sep-20-2021

2021-09-16 14:42:00

Vertex Pharmaceuticals Incorporated Presents at Cell & Gene Therapy Bioprocessing & Commercialization, Sep-20-2021 . Speakers: Stacey Veysey, Director, Talent Acquisition.

Neutral

Vertex Pharmaceuticals Incorporated Provides Earnings Guidance for the Year 2021

2021-09-15 15:00:00

Vertex Pharmaceuticals Incorporated provided earnings guidance for the year 2021. For the period, the company raised revenue guidance by $500 million. And the midpoint of guidance range, $7.3 billion, represents 18% growth over 2020.

Neutral

Vertex Pharmaceuticals Incorporated Presents at 10th Annual Sickle Cell Disease Therapeutics Conference, Sep-15-2021 03:25 PM

2021-09-15 13:42:00

Vertex Pharmaceuticals Incorporated Presents at 10th Annual Sickle Cell Disease Therapeutics Conference, Sep-15-2021 03:25 PM. Speakers: William Hobbs, Vice President, Clinical Development, Vertex Cell and Genetic Therapies.

Neutral

Vertex Pharmaceuticals Incorporated Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-15-2021 11:00 AM

2021-09-13 12:00:00

Vertex Pharmaceuticals Incorporated Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-15-2021 11:00 AM. Venue: New Windsor, United States.

Positive

Obsidian Therapeutics, Inc. announced that it has received $114.999999 million in funding from a group of investors

2021-09-09 00:00:00

On September 9, 2021, Obsidian Therapeutics, Inc. closed the transaction. The company issued 76,158,940 shares and received $114,999,999.4 in a round of funding led by new investor TTCG Crossover Management, LLC. The transaction included participation form Vertex Pharmaceuticals Incorporated, new investors RA Capital Management, L.P, Citadel Multi-Strategy Equities Master Fund Ltd. a fund managed by Citadel Advisors LLC, Cowen Healthcare Investments, Deep Track Capital, LP, Logos Capital LLC, Pivotal BioVenture Partners LLC, Samsara BioCapital LLC, Soleus Capital, returning investors Atlas Venture L.P, Vertex Ventures HC, Amgen Ventures, and Bristol-Myers Squibb Company. As part of the transaction Cariad Chester from TCG Crossover Management, LLC had joined the company's board.

Neutral

Informa plc, Cell & Gene Therapy Bioprocessing & Commercialization, Sep 20, 2021 through Sep 30, 2021

2021-09-08 23:01:00

Informa plc, Cell & Gene Therapy Bioprocessing & Commercialization, Sep 20, 2021 through Sep 30, 2021.

Neutral

Global Blood Therapeutics, Inc., Sickle Cell Disease Association of America, Inc., 10th Annual Sickle Cell Disease Therapeutics Conference, Sep 15, 2021

2021-09-08 21:05:00

Global Blood Therapeutics, Inc., Sickle Cell Disease Association of America, Inc., 10th Annual Sickle Cell Disease Therapeutics Conference, Sep 15, 2021.

Neutral

LSX Ltd, 5th LSX USA Congress & CEO Forums, Jun 21, 2022 through Jun 22, 2022

2021-09-04 07:34:00

LSX Ltd, 5th LSX USA Congress & CEO Forums, Jun 21, 2022 through Jun 22, 2022. Venue: Boston, United States.

Positive

Vertex Pharmaceuticals Incorporated Announces Publication in The New England Journal of Medicine of Phase 3 Results for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People With Cystic Fibrosis

2021-08-26 11:00:00

Vertex Pharmaceuticals Incorporated announced publication in The new England Journal of Medicine(NEJM) of results from a Phase 3 study of TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in people with cystic fibrosis (CF) ages 12 years and older who have one copy of the F508del mutation and one gating (F/G) or residual function (F/RF) mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The manuscript includes data on primary and key secondary endpoints, which were previously reported and showed statistically significant and clinically meaningful improvements in lung function and sweat chloride, when compared to active control (either ivacaftor or tezacaftor/ivacaftor), as well as more detailed efficacy and safety data, including subgroup efficacy analyses. Study 445-104: The data published are from a global Phase 3, randomized, double-blind, parallel-group study. All patients had a 4-week run-in period of either ivacaftor or tezacaftor/ivacaftor. Following the run-in, 258 patients were randomized to receive TRIKAFTA or to remain on their prior regimen of ivacaftor or tezacaftor/ivacaftor for 8 weeks. Baseline was measured at the end of the run-in period, prior to the start of the 8-week treatment period. TRIKAFTA improved the percent predicted forced expiratory volume in 1 second (ppFEV1) by 3.7 percentage points (95% CI, 2.8 to 4.6; P<0.001) from baseline and by 3.5 percentage points (95% CI, 2.2 to 4.7; P<0.001) vs. active control and improved sweat chloride concentration by -22.3 mmol/liter (95% CI, -24.5 to -20.2; P<0.001) from baseline and by -23.1 mmol/liter (95% CI, -26.1 to -20.1; P<0.001) vs. active control. The change in the CFQ-R respiratory domain score was +10.3 points from baseline (95% CI, 8.0 to 12.7) and +8.7 points vs. active control (95% CI, 5.3 to 12.1). Subgroup analyses of patients with F/G and F/RF genotypes are also included in the manuscript. Safety data were consistent with those observed in previous Phase 3 studies with TRIKAFTA.

Positive

Vertex Pharmaceuticals Incorporated and Arbor Biotechnologies Establish New Partnership to Develop Novel Ex Vivo Engineered Cell Therapies

2021-08-24 11:00:00

Vertex Pharmaceuticals Incorporated and Arbor Biotechnologies (Arbor) announced a new collaboration to enhance efforts in developing ex vivo engineered cell therapies, using Arbor’s proprietary CRISPR gene-editing technology for select diseases. The new agreement between Arbor and Vertex builds upon the companies’ first partnership established in 2018. Under this new partnership, Vertex will receive rights to use Arbor’s technology to research and develop ex vivo engineered cell therapies towards Vertex’s goal of generating fully differentiated, insulin-producing hypoimmune islet cells for the treatment of type 1 diabetes, for next-generation approaches in sickle cell disease and beta thalassemia, and for the treatment of other diseases.

Neutral

Vertex Pharmaceuticals Incorporated Presents at World Orphan Drug Congress USA 2021, Aug-26-2021 01:00 PM

2021-08-20 20:21:00

Vertex Pharmaceuticals Incorporated Presents at World Orphan Drug Congress USA 2021, Aug-26-2021 01:00 PM. Venue: Gaylord National Resort & Convention Center, Oxon Hill, Maryland, United States. Speakers: Ali Mohamadi, Executive Director.

Neutral

Terrapinn Holdings Ltd, World Orphan Drug Congress USA 2021, Aug 25, 2021 through Aug 27, 2021

2021-08-20 17:31:00

Terrapinn Holdings Ltd, World Orphan Drug Congress USA 2021, Aug 25, 2021 through Aug 27, 2021. Venue: Gaylord National Resort & Convention Center, Oxon Hill, Maryland, United States.

Positive

Obsidian Therapeutics, Inc. announced that it expects to receive $115.043755 million in funding

2021-08-19 00:00:00

Obsidian Therapeutics, Inc. announced that it will issue 7,6187,917 series B Preferred shares at an issue price of $1.51 per share for gross proceeds of $115,043,755 in funding on August 19, 2021. The shares are convertible into equity shares at an conversion price of $1.51 per share. The round will be raised at post money valuation of $211,576,057.

Neutral

Vertex Pharmaceuticals Incorporated Presents at Supply Chain & Logistics for Cell Therapies Summit, Oct-26-2021 through Oct-28-2021

2021-08-14 17:42:00

Vertex Pharmaceuticals Incorporated Presents at Supply Chain & Logistics for Cell Therapies Summit, Oct-26-2021 through Oct-28-2021. Presentation Date & Speakers: Oct-27-2021, Nicole Rickard, Head of Supply Chain, Cell & GTx. Oct-28-2021, Nicole Rickard, Head of Supply Chain.

Neutral

Hanson Wade Limited, Supply Chain & Logistics for Cell Therapies Summit, Oct 26, 2021 through Oct 28, 2021

2021-08-14 15:18:00

Hanson Wade Limited, Supply Chain & Logistics for Cell Therapies Summit, Oct 26, 2021 through Oct 28, 2021.

Neutral

Vertex Pharmaceuticals Incorporated Presents at Pharma & Patient USA, Nov-02-2021 10:00 AM

2021-08-05 08:52:00

Vertex Pharmaceuticals Incorporated Presents at Pharma & Patient USA, Nov-02-2021 10:00 AM. Speakers: Gokul Gopalan, VP, Global Medical Affairs.

Neutral

Reuters Events, Pharma & Patient USA, Nov 02, 2021 through Nov 04, 2021

2021-08-05 03:58:00

Reuters Events, Pharma & Patient USA, Nov 02, 2021 through Nov 04, 2021.

Negative

Vertex Pharmaceuticals Incorporated Appoints Stuart A. Arbuckle as Executive Vice President and Chief Operating Officer

2021-08-04 12:30:00

Vertex Pharmaceuticals Incorporated announced that Stuart A. Arbuckle has been appointed as the company’s Executive Vice President, Chief Operating Officer (COO), effective immediately. Mr. Arbuckle has served as Vertex’s Executive Vice President and Chief Commercial Officer since 2012 and expanded his role to include oversight of operations earlier this year. As Vertex’s COO, Mr. Arbuckle oversees Vertex’s global Commercial team, which is responsible for the company’s reimbursement and access, sales, marketing, patient support, market research, as well as Commercial Manufacturing and Supply Chain, and other activities that support the approved use of Vertex’s marketed medicines around the world. Mr. Arbuckle also oversees the Human Resources and Corporate Communications functions. Mr. Arbuckle has more than 30 years of experience leading global sales and marketing efforts at biopharmaceutical companies, including at Amgen and GlaxoSmithKline plc. Mr. Arbuckle currently serves as a member of Rhythm Pharmaceuticals and ImmunoGen's board of directors, as a national board member of the Cancer Support Community, and on the Executive Committee and Health Section Governing Board for the Biotechnology Innovation Organization (BIO). He is also co-chair of the BIO Standing Committee on Access & Value.

Neutral

Tranche Update on Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX)'s Equity Buyback Plan announced on June 24, 2021.

2021-07-30 16:11:00

From June 23, 2021 to June 30, 2021, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 0 shares, representing 0% for $0 million under the buyback announced on June 24, 2021.

Neutral

Vertex Pharmaceuticals Incorporated Provides Earnings Guidance for the Fiscal Year 2021

2021-07-29 20:01:00

Vertex Pharmaceuticals Incorporated increased its full-year 2021 product revenue guidance based on strong year-to-date performance and the expected impact of recent reimbursement agreements. For the year, the company expects product revenues in range of $7.2 to 7.4 billion compared to previously fiscal year $6.7 to 6.9 billion.

Positive

Vertex Pharmaceuticals Incorporated Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain

2021-07-19 12:00:00

Vertex Pharmaceuticals Incorporated announced that it has begun a Phase 2 proof-of-concept (POC) study in acute pain following bunionectomy surgery with the selectiveNaV1.8 inhibitor VX-548 and that it expects to commence a second Phase 2 study in acute pain following abdominoplasty surgery in the coming weeks. The Phase 2 studies are randomized, double-blind, placebo-controlled trials that will evaluate multiple doses of VX-548 in patients with acute pain following bunionectomy surgery or abdominoplasty surgery. Both studies will also include a hydrocodone bitartrate /acetaminophen reference arm. The primary endpoint in both studies is the time-weighted Sum of the Pain Intensity Difference over the first 48 hours of treatment (SPID48). VX-548 is an oral, selective NaV1.8 inhibitor that has completed Phase 1 studies in healthy volunteers. Based on a favorable pharmacokinetic, safety and tolerability profile, it was advanced to Phase 2 studies in 2021. NaV1.8 is a voltage-gated sodium channel that plays a critical role in pain signaling in the peripheral nervous system. NaV1.8 is a genetically validated novel target for the treatment of pain, and Vertex has previously demonstrated clinical proof-of-concept with a small molecule investigational treatment targeting NaV1.8 in multiple pain indications including acute pain, neuropathic pain and musculoskeletal pain. Vertex’s approach is to selectively inhibit NaV1.8 using small molecules with the objective of creating a new class of medicines that have the potential to provide superior relief of acute pain without the limitations of opioids, including their addictive potential. VX-548 is the most recent molecule to enter clinical development from Vertex’s portfolio of NaV1.8 inhibitors.

Neutral

Vertex Pharmaceuticals Incorporated, Q2 2021 Earnings Call, Jul 29, 2021

2021-07-16 20:01:00

Vertex Pharmaceuticals Incorporated, Q2 2021 Earnings Call, Jul 29, 2021

Neutral

Vertex Pharmaceuticals Incorporated to Report Q2, 2021 Results on Jul 29, 2021

2021-07-16 20:01:00

Vertex Pharmaceuticals Incorporated announced that they will report Q2, 2021 results After-Market on Jul 29, 2021

Fundamental Summary

At a high level, the metrics from Vertex Pharmaceuticals's Q1 financial report release provided many positive indicators. Specifically, their growth, value, and income factors indicate a well-planned and balanced effort, which is generating exciting growth. We expect that this positive performance will continue in the coming months, and anticipate that Vertex Pharmaceuticals will maintain good momentum even in a challenging environment. Therefore, they earned a total score of 79 out of 100 and a BUY recommendation.

Vertex Pharmaceuticals reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 2,097.5 million compared to USD 1,724.3 million a year ago. Net income was USD 762.1 million compared to USD 653.1 million a year ago. Basic earnings per share from continuing operations was USD 2.99 compared to USD 2.52 a year ago. Diluted earnings per share from continuing operations was USD 2.96 compared to USD 2.49 a year ago.

Business Description

Vertex Pharmaceuticals, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals was founded in 1989 and is headquartered in Boston, Massachusetts.

Sector Overview

Vertex Pharmaceuticals is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Vertex Pharmaceuticals's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 14,256.1 6.1% 69
Liabilities 3,349.1 0.5% 69
Price to Book 6.1 10.0% 92
Cash & Equivalents 7,600.1 11.8% 84
Equity 10,907.0 8.0% 58
EBITDA 3,098.3 5.5% 80
Total Revenues 7,947.6 4.9% 57
Parameter Value Change Score
Return on Equity 24.6 -1.1% 62
Net Cashflow 1,291.1 59.2% 64
Capital Expenditure -227.7 3.1% 80
Asset Turnover 0.6 0.2% 71
Free Cashflow 9.6 2.2% 75

* All values are TTM

The below chart reflects Vertex Pharmaceuticals's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Vertex Pharmaceuticals's peer average final assessment score stands on 66.0, Vertex Pharmaceuticals's score is 79.

  •  VRTX
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Amgen Inc. 130.1B 69 78 81
Hold
77
77 0 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 1 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 2 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 3 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 4 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 5 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 6 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 7 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 8 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 9 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 10 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 11 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 12 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 13 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 14 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 15 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 16 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 17 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 18 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 19 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 20 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 21 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 22 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 23 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 25 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 27 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 28 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 29 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 30 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 31 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 32 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 33 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 35 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 36 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 37 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 38 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 39 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 40 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 41 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 42 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 43 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 45 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 46 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 47 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 48 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 49 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 50 1
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 51 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 52 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 53 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 54 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 55 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 56 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 57 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 58 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 59 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 60 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 61 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 62 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 63 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 64 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 65 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 66 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 67 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 68 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 69 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 70 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 73 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 74 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 75 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 77 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 78 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 79 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 80 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 81 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 82 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 83 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 84 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 85 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 86 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 87 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 88 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 89 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 90 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 91 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 92 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 93 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 94 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Vertex Pharmaceuticals's stock is now priced above its 50-day and 200-day, but below its 5-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is strengthening. Historically, this is a positive setup in the medium and long-term. In particular, many institutional investors keep close watch of the 200-day moving average. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Vertex Pharmaceuticals's stock appears overbought. Overall, these technical indicators don't clearly signal directional momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 62.

Neutral 62
Close Price 276.17
52W Low 177.01
52W High 292.55
5D MA 282.37
50D MA 265.16
200D MA 228.94
MACD 4.82
RSI 87.34
STOCH 65.27

Balance Sheet Analysis

Two metrics jump up as the most significant positive drivers of the balance sheet strength in Vertex Pharmaceuticals's recent report: Book Value Factors and Cash & Equivalents. Vertex Pharmaceuticals's price to book ratio (P/B) was reported as 6.1 and represents 10.0% change from the previous report. These book value factor numbers show that management has been prudent in focusing on efficient growth. We believe the stock price has room to grow to reflect its intrinsic value accurately. The company's book value factors component, therefore, received a grade of 92. Also, Vertex Pharmaceuticals's management was effective in improving its cash and cash equivalents metrics, which now sit at 7600.1. This represents 11.8% change from the last reporting period. This performance is significantly more impressive than its peers and competitors. It suggests that their stock price has room to grow to reflect its actual intrinsic value. Therefore, its cash and cash equivalents movement earned a score of 84. At the same time, one critical balance sheet metric, Equity, was notably weak. Vertex Pharmaceuticals published concerning equity metrics for this filing. In the current report, equity stood at 10907.0, which represents a 8.0% change from the last report. This parameter often affects companies in the same industry and market capitalization by up to 7.3%. This performance is significantly less impressive than its peers and competitors. Consequently, their equity movement received a grade of 58. Similarly, because the company's management is doing an excellent job managing these critical metrics, the balance sheet was given a score of 78.

Parameter Value Change Score
Assets 14,256.1 6.1% 69
Liabilities 3,349.1 0.5% 69
Price to Book 6.1 10.0% 92
Cash & Equivalents 7,600.1 11.8% 84
Equity 10,907.0 8.0% 58
* All values are TTM

The below chart describes Vertex Pharmaceuticals's performance as reflected on its balance sheet with respect to its peers. While Vertex Pharmaceuticals received a balance sheet score of 78, the average of its peers stands on 66.0.

  •  VRTX
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Amgen Inc. 130.1B 72 68 86 53 62 69 0 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 1 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 2 1
BioNTech SE 34.0B 75 69 64 97 73 75 3 1
Seagen Inc. 32.9B 59 68 55 43 66 61 4 1
Biogen Inc. 29.7B 57 72 92 50 76 76 5 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 6 1
Incyte Corporation 16.8B 71 72 95 82 79 83 7 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 8 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 9 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 10 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 11 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 12 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 13 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 14 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 15 1
Alkermes plc 5.0B 63 66 46 54 71 62 16 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 17 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 18 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 19 1
Natera, Inc. 3.6B 73 65 43 95 42 54 20 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 21 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 22 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 23 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 25 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 27 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 28 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 29 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 30 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 31 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 32 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 33 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 35 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 36 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 37 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 38 1
Geron Corporation 566.2M 69 72 37 59 62 60 39 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 40 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 41 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 42 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 43 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 45 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 46 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 47 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 48 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 49 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 50 1
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 51 1
CureVac N.V. 2.6B 49 64 75 52 52 57 52 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 53 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 54 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 55 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 56 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 57 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 58 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 59 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 60 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 61 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 62 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 63 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 64 1
CareDx, Inc 1.2B 54 67 52 39 51 52 65 1
Vericel Corporation 1.1B 51 65 56 53 61 57 66 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 67 1
MannKind Corporation 957.2M 79 59 50 40 64 57 68 1
Merus N.V. 941.6M 59 68 50 83 81 70 69 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 70 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 73 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 74 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 75 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 76 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 77 1
Immatics N.V. 538.7M 56 70 84 95 73 76 78 1
Agenus Inc. 520.5M 73 62 37 55 60 54 79 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 80 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 81 1
Affimed N.V. 415.0M 56 66 63 56 47 54 82 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 83 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 84 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 85 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 86 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 87 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 88 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 89 1
AC Immune SA 299.8M 84 64 47 53 75 68 90 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 91 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 92 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 93 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 94 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

Vertex Pharmaceuticals appears likely to maintain its strong income statement metrics and momentum going forward. Vertex Pharmaceuticals's management was effective in improving its EBIDTA, which now sits at 3098.3 and represents a 5.5% change from the last reporting period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 24.4%. Their EBITDA metrics are even more impressive relative to their peers and competitors, and its likely the stock price has room to grow to reflect its intrinsic value accurately. The company's EBITDA movement, therefore, received a grade of 80. Also, Return factors metrics and ratios were exceptional in this report. Vertex Pharmaceuticals reported a return on equity (ROE) ratio of 24.6, representing a change of -1.1% from the last report. These numbers show that management has successfully encouraged growth while managing ROE and ROA metrics, especially relative to their peers. The company's return factors (ROA & ROE) components, therefore, received a grade of 62. On the other hand, Revenue Efficiency, jumped out as looking rather underwhelming. Vertex Pharmaceuticals management did an underwhelming job managing revenue efficiency this past period. Vertex Pharmaceuticals's revenue efficiency is 7947.6 according to the metrics in the current filing, which represents a 4.9% change from the previous report. This metric might have a 13.1 percent impact on companies in the same industry and with the same market capitalization. Its uninspiring revenue efficiency is even more concerning relative to its peers and competitors in the current market. Consequently, their revenue efficiency received a grade of 57. Therefore, their income statement earned a grade of 75.

Parameter Value Change Score
EBITDA 3,098.3 5.5% 80
Total Revenues 7,947.6 4.9% 57
Return on Equity 24.6 -1.1% 62
* All values are TTM

The below chart describes Vertex Pharmaceuticals's performance as reflected on its income statement with respect to its peers. While Vertex Pharmaceuticals received a income statement score of 75 , the average of its peers stands on 68.0.

  •  VRTX
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Amgen Inc. 130.1B 74 75 64 78 0 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 1 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 2 1
BioNTech SE 34.0B 41 89 75 79 3 1
Seagen Inc. 32.9B 54 65 70 62 4 1
Biogen Inc. 29.7B 90 57 73 70 5 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 6 1
Incyte Corporation 16.8B 59 77 60 73 7 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 8 1
United Therapeutics Corporation 10.6B 57 91 54 82 9 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 10 1
Exelixis, Inc. 6.7B 54 91 54 81 11 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 12 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 13 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 14 1
Ascendis Pharma A/S 5.2B 38 68 46 54 15 1
Alkermes plc 5.0B 69 55 81 62 16 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 17 1
Novavax, Inc. 4.0B 41 89 54 75 18 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 19 1
Natera, Inc. 3.6B 52 51 78 52 20 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 21 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 22 1
Insmed Incorporated 2.4B 51 58 73 57 23 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 25 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 27 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 28 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 29 1
IVERIC bio, Inc. 1.1B 84 58 79 70 30 1
FibroGen, Inc. 1.0B 48 74 63 67 31 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 32 1
ImmunoGen, Inc. 946.1M 40 73 71 64 33 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 35 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 36 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 37 1
AnaptysBio, Inc. 586.3M 97 50 77 68 38 1
Geron Corporation 566.2M 89 67 73 78 39 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 40 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 41 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 42 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 43 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 45 1
Precigen, Inc. 299.1M 57 87 59 79 46 1
bluebird bio, Inc. 288.7M 99 91 61 96 47 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 48 1
MacroGenics, Inc. 184.6M 95 56 74 71 49 1
Exact Sciences Corporation 7.2B 57 67 54 62 50 1
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 51 1
CureVac N.V. 2.6B 45 83 71 74 52 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 53 1
Abgenix Inc. 2.1B 47 47 47 47 54 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 55 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 56 1
Xencor, Inc. 1.6B 42 94 52 79 57 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 58 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 59 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 60 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 61 1
Veracyte, Inc. 1.4B 45 63 57 55 62 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 63 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 64 1
CareDx, Inc 1.2B 61 44 82 50 65 1
Vericel Corporation 1.1B 76 44 82 56 66 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 67 1
MannKind Corporation 957.2M 95 48 56 61 68 1
Merus N.V. 941.6M 48 60 59 54 69 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 70 1
Amarin Corporation plc 734.5M 95 44 82 63 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 72 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 73 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 74 1
CTI BioPharma Corp. 603.6M 84 50 62 59 75 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 77 1
Immatics N.V. 538.7M 37 93 53 77 78 1
Agenus Inc. 520.5M 57 83 45 74 79 1
Radius Health, Inc. 499.8M 94 71 68 82 80 1
Vaxart, Inc. 440.0M 99 51 72 68 81 1
Affimed N.V. 415.0M 95 49 75 66 82 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 83 1
MiMedx Group, Inc. 391.5M 87 43 83 59 84 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 85 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 86 1
Zymeworks Inc. 324.7M 58 53 77 56 87 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 88 1
Silence Therapeutics plc 313.4M 83 64 69 72 89 1
AC Immune SA 299.8M 83 61 65 70 90 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 91 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 92 1
Chimerix, Inc. 178.4M 99 50 62 65 93 1
DermTech, Inc. 165.3M 49 48 78 52 94 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Vertex Pharmaceuticals appears likely to maintain its strong cash flow metrics and momentum going forward. Vertex Pharmaceuticals's management did a great job this period managing its capital expenditure (CapEx). In terms of the raw numbers, CapEx was reported as -227.7, which represents a 3.1% change from the last period. This performance is all the more impressive relative to their peers and competitors. The company's CapEx movement, therefore, received a grade of 80. Also, Free cash flow numbers published by Vertex Pharmaceuticals were 9.6, which was a 2.2% change from the previous filing. This parameter coud affect companies in the same industry and market capitalization by up to 2.6%. The company's free cash flow metrics are especially strong compared to its peers. Management seems to balance cash flow management, asset growth, and resource allocations in general. Therefore, its free cash flow movement earned a score of 75. At the same time, one critical cash flow metric, Net Cash Flow, was notably weak. Vertex Pharmaceuticals's produced underwhelming cash flow numbers in this filing. Net cash flow was reported as 1291.1, which is a 59.2% change from the last report. Vertex Pharmaceuticals's net cash flow metrics are especially disappointing relative to their peers. Consequently, their net cash flow movement received a grade of 64. Therefore, the company's cash flow earned a grade of 71.

Parameter Value Change Score
Net Cashflow 1,291.1 59.2% 64
Capital Expenditure -227.7 3.1% 80
Asset Turnover 0.6 0.2% 71
Free Cashflow 9.6 2.2% 75
* All values are TTM

The below chart describes Vertex Pharmaceuticals's performance as reflected on its cash flow with respect to its peers. While Vertex Pharmaceuticals received a cash flow score of 71, the average of its peers stands on 69.0.

  •  VRTX
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Amgen Inc. 130.1B 80 74 67 74 81 0 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 1 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 2 1
BioNTech SE 34.0B 73 97 50 52 72 3 1
Seagen Inc. 32.9B 53 53 50 87 58 4 1
Biogen Inc. 29.7B 58 54 90 73 66 5 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 6 1
Incyte Corporation 16.8B 78 79 92 74 84 7 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 8 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 9 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 10 1
Exelixis, Inc. 6.7B 79 90 89 83 87 11 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 12 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 13 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 14 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 15 1
Alkermes plc 5.0B 89 95 76 80 92 16 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 17 1
Novavax, Inc. 4.0B 62 38 63 54 60 18 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 19 1
Natera, Inc. 3.6B 52 54 56 84 58 20 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 21 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 22 1
Insmed Incorporated 2.4B 79 80 61 89 82 23 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 25 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 27 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 28 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 29 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 30 1
FibroGen, Inc. 1.0B 86 74 48 87 84 31 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 32 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 33 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 35 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 36 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 37 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 38 1
Geron Corporation 566.2M 78 68 49 81 77 39 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 40 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 41 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 42 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 43 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 45 1
Precigen, Inc. 299.1M 82 75 37 85 74 46 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 47 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 48 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 49 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 50 1
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 51 1
CureVac N.V. 2.6B 87 80 90 70 90 52 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 53 1
Abgenix Inc. 2.1B 66 53 45 59 58 54 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 55 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 56 1
Xencor, Inc. 1.6B 96 95 70 95 98 57 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 58 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 59 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 60 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 61 1
Veracyte, Inc. 1.4B 90 95 46 46 82 62 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 63 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 64 1
CareDx, Inc 1.2B 98 84 40 50 86 65 1
Vericel Corporation 1.1B 64 46 59 73 65 66 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 67 1
MannKind Corporation 957.2M 77 56 43 37 66 68 1
Merus N.V. 941.6M 70 71 74 53 71 69 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 70 1
Amarin Corporation plc 734.5M 52 40 74 55 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 72 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 73 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 74 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 75 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 76 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 77 1
Immatics N.V. 538.7M 82 95 56 99 86 78 1
Agenus Inc. 520.5M 57 43 52 77 58 79 1
Radius Health, Inc. 499.8M 64 40 37 56 57 80 1
Vaxart, Inc. 440.0M 72 56 53 38 65 81 1
Affimed N.V. 415.0M 72 57 95 43 74 82 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 83 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 84 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 85 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 86 1
Zymeworks Inc. 324.7M 52 65 45 83 57 87 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 88 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 89 1
AC Immune SA 299.8M 66 77 79 63 68 90 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 91 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 92 1
Chimerix, Inc. 178.4M 80 84 95 47 83 93 1
DermTech, Inc. 165.3M 60 51 45 86 58 94 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.